TL;DR: 🟢 Positive — IV pantoprazole significantly reduced clinically important GI bleeding (1.0% vs 3.5%) in mechanically ventilated patients with no mortality penalty (HR 0.94).
1. Publication
- Title: Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation
- Acronym: REVISE
- Year & Journal: New England Journal of Medicine, published June 14, 2024 (391(1):9-20)
- Citation: Cook D, Deane A, Lauzier F, et al. N Engl J Med. 2024;391(1):9-20. doi:10.1056/NEJMoa2404245
2. Context & Rationale
Background: Stress-related mucosal disease causes upper GI bleeding in critical illness, though contemporary incidence has fallen with modern ICU practices. Prior evidence (SUP-ICU) showed no overall mortality benefit from PPI prophylaxis but suggested harm in the most severely ill subgroup; PEPTIC also trended toward possible harm with PPI vs H2RA — leaving genuine equipoise.
Research Question/Hypothesis: In mechanically ventilated adults, does IV pantoprazole reduce clinically important upper GI bleeding at 90 days compared with placebo, without increasing mortality?
3. Design & Methods
- Study Type: Investigator-initiated, randomized, placebo-controlled, multicenter, triple-blinded trial
- Setting & Centers: International; July 2019–October 2023
- Population: Mechanically ventilated critically ill adults
- Intervention: IV pantoprazole 40mg daily, for up to 90 days or until MV discontinuation
- Comparator: Placebo (0.9% saline)
- Blinding: Triple-blind
- Statistical Power & Follow-Up: Primary efficacy: clinically important upper GI bleeding at 90 days. Primary safety: 90-day mortality.
4. Key Results
Outcome | Pantoprazole | Placebo | Effect Size | Notes |
Clinically important upper GI bleeding (primary efficacy) | 1.0% | 3.5% | 95% CI for difference: 1.6–3.3pp | Significant reduction |
Patient-important upper GI bleeding | 1.5% | 4.2% | — | Also significantly reduced |
90-day mortality (primary safety) | 29.1% | 30.9% | HR 0.94 | Not significantly different |
Ventilator-associated pneumonia, C. diff, LOS | No significant difference | No significant difference | — | No safety penalty |
5. Internal Validity Assessment
Large, triple-blind, placebo-controlled, adequately powered RCT. Overall: Strong — clean, statistically robust efficacy result with no safety penalty; described by ACG summary as "a large, adequately powered trial that addresses limitations from earlier trials."
6. External Validity Assessment
International, multicenter mechanically ventilated ICU population — broadly representative of modern ventilated ICU practice.
7. Strengths & Limitations
Strengths: Triple-blind design; large sample; addresses both efficacy and safety explicitly; no significant harm signal despite prior concerns from SUP-ICU/PEPTIC.
Limitations: Lacks patient-reported disability outcomes and microbiome data per the authors' own acknowledgment; a concurrent meta-analysis (REVISE+SUP-ICU) suggested possible mortality benefit in less severely ill patients but not more severely ill ones — an important nuance for the sickest patients.
8. Interpretation & Practice Impact
Supports routine IV pantoprazole for stress ulcer prophylaxis in mechanically ventilated patients — reduces clinically and patient-important GI bleeding without a mortality penalty, reassuring after prior uncertainty from SUP-ICU and PEPTIC.
9. Controversies & Subsequent Evidence
An accompanying NEJM editorial ("Uncertain Answers — Proton-Pump Inhibition in the ICU," Brown) acknowledges REVISE was well-designed and its results reassuring, but notes that between REVISE and SUP-ICU, the mortality question in the most severely ill patients remains uncertain. A concurrent meta-analysis combining REVISE and SUP-ICU data found decreased mortality among less severely ill patients but not among more severely ill ones — suggesting individualized use (reserving PPI for those with clear risk factors) in the sickest patients may be reasonable.
10. Summary & Executive Takeaway
Summary: REVISE, a large triple-blind RCT, randomized mechanically ventilated ICU patients to IV pantoprazole or placebo. Pantoprazole significantly reduced clinically important (1.0% vs 3.5%) and patient-important (1.5% vs 4.2%) upper GI bleeding, with no significant effect on 90-day mortality (29.1% vs 30.9%, HR 0.94).
Overall Takeaway: IV pantoprazole meaningfully reduces upper GI bleeding in mechanically ventilated patients without a mortality penalty — supporting continued routine stress ulcer prophylaxis, though a combined meta-analysis suggests the mortality picture may still differ for the most severely ill patients.
11. Bibliography
- Krag M, Marker S, Perner A, et al. Pantoprazole in patients at risk for GI bleeding in the ICU (SUP-ICU). N Engl J Med. 2018;379(23):2199-2208.
- PEPTIC Investigators. Effect of stress ulcer prophylaxis with PPIs vs H2RAs on in-hospital mortality (PEPTIC). JAMA. 2020;323:616-626.
- Brown SM. Uncertain Answers — Proton-Pump Inhibition in the ICU [editorial]. N Engl J Med. 2024;391(1):78-79.